*Corresponding author:Dr Mark A Baxter, Department of Medical Oncology, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, UK Email: firstname.lastname@example.org
Received: August 07, 2018; Published: August 10, 2018
To view the Full Article Peer-reviewed Article PDF
Sorafenib is the current first line standard of care in patients with advanced hepatocellular carcinoma (HCC). Several other drugs are emerging as efficacious agents in this setting. This article will outline our current real-world experience with sorafenib in a Scottish population as well as discuss the evidence behind new potential therapies.
Keywords: Sorafenib; Hepatocellular carcinoma; HCC
Abbreviations: HCC: Hepatocellular Carcinoma; PS: Performance Status; OS: Overall Survival; TACE: Transarterial Chemoembolization; VEGF: Vascular Endothelial Growth Factor; PDGFR: Platelet Derived Growth Factor Receptor; FGFR: Fibroblast Growth Factor Receptor; WoS: West of Scotland
We know the financial complexity of Individual read more...
The annual scholar awards from Lupine Publishers honor a selected number read more...